Home > Journals > International Angiology > Past Issues > International Angiology 2019 August;38(4) > International Angiology 2019 August;38(4):299-304

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

 

ORIGINAL ARTICLE  PERIPHERAL ARTERIAL DISEASE Freefree

International Angiology 2019 August;38(4):299-304

DOI: 10.23736/S0392-9590.19.04199-3

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Safety and effectiveness of a new valvulotome: insights from the LIMBSAVE registry

Nicola TROISI 1 , Giovanni DE BLASIS 2, Mauro SALVINI 3, Stefano MICHELAGNOLI 1, on behalf of LIMBSAVE registry Collaborative Group 

1 Unit of Vascular and Endovascular Surgery, Department of Surgery, San Giovanni di Dio Hospital, Florence, Italy; 2 Unit of Vascular Surgery, Santi Filippo e Nicola Hospital, Avezzano, L’Aquila, Italy; 3 Unit of Vascular Surgery, Santi Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy



BACKGROUND: In the endovascular era peripheral bypass surgery still plays a key role. In situ saphenous vein bypass is a standardized technique. The main limitation of this procedure is the vein diameter. A new hydrophylic valvulotome (HYDRO LeMaitre® Valvulotome; LeMaitre Vascular, Burlington, MA, USA) allows even to disrupt the valves in smaller veins. The aim of this study was to analyze the intraprocedural and technical successes of this new valvulotome.
METHODS: In January 2018 in Italy a national, multicenter, observational, prospective registry based on the examination of treatment of critical limb ischemia with infragenicular bypass adopting in situ saphenous vein technique (LIMBSAVE registry) started the enrollment. Until December 2018 216 patients have been enrolled in the registry. All data concerning the procedures were prospectively collected in a dedicated database. The information included demographics, preoperative risk factors, clinical and diagnostic preoperative assessments, intraoperative features, and discharge outcomes, including the safety and effectiveness of the valvulotome during the surgical procedure.
RESULTS: Patients were predominantly male (160, 74.1%) with a mean age of 74.1 years (range 49-95). The mean diameter of the great saphenous vein was 3.7 mm (range 1.7-10) in the proximal part of the thigh, 3.4 mm (range 1.6-7) in the distal part of the thigh, and 3.1 mm in the proximal part of the leg (range 1.6-5). The technical success was obtained in all cases (the bypass pulsed after the utilization of the valvulotome). The valvulotome was able to reach the proximal anastomosis in all cases. The mean number of utilizations was 2.6 (range 1-5). No vein perforation has been detected. In 6 cases (2.8%) a vein adventitial damage occurred. In one case with uncontrolled bleeding (0.5%) the substitution of the deleted vein segment was necessary.
CONCLUSIONS: Preliminary intraprocedural outcomes of LIMBSAVE registry showed that HYDRO LeMaitre® Valvulotome was safe and effective in disrupting the valves and obtaining the pulsatility of the saphenous vein. The rate of complications related to the utilization of the valvulotome was low. Further examinations are needed to evaluate the long-term outcomes of the bypass in terms of patency, reinterventions, and limb salvage.


KEY WORDS: Ischemia; Limb salvage; Saphenous vein

top of page